chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 41.0
Sex: F
Vaccine: UNK, COVID19
Symptoms: Dysgeusia, Fatigue, Flushing, Headache, Pain in extremity
Clinical narrative: very sore at injection site, unable to lift arm; metallic taste in mouth; extreme fatigue; nausea; headache; unable to lift arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. The patient did not have medical history. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID) and venlafaxine (MANUFACTURER UNKNOWN) for unspecified indications from unspecified dates and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since having the vaccine. On 25Mar2021 at 14:30, the patient experienced extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain/very sore at injection site (unable to sleep on vaccinated side) unable to lift arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain and unable to lift arm was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: UNK, COVID19
Symptoms: Dysgeusia, Fatigue, Headache, Limb discomfort, Nausea
Clinical narrative: very sore at injection site, unable to lift arm; metallic taste in mouth; extreme fatigue; nausea; headache; unable to lift arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. The patient did not have medical history. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID) and venlafaxine (MANUFACTURER UNKNOWN) for unspecified indications from unspecified dates and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since having the vaccine. On 25Mar2021 at 14:30, the patient experienced extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain/very sore at injection site (unable to sleep on vaccinated side) unable to lift arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain and unable to lift arm was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: UNK, COVID19
Symptoms: Vaccination site pain
Clinical narrative: very sore at injection site, unable to lift arm; metallic taste in mouth; extreme fatigue; nausea; headache; unable to lift arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 25Mar2021 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. The patient did not have medical history. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN), levothyroxine sodium (SYNTHROID) and venlafaxine (MANUFACTURER UNKNOWN) for unspecified indications from unspecified dates and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since having the vaccine. On 25Mar2021 at 14:30, the patient experienced extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain/very sore at injection site (unable to sleep on vaccinated side) unable to lift arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of extreme fatigue, headache, metallic taste in mouth, nausea and vaccination site pain and unable to lift arm was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Chest X-ray normal, Chest discomfort, Chest pain, Electrocardiogram normal
Clinical narrative: sharp pain/pressure in chest; sharp pain/pressure in chest; elevated heart rate; sharp pains in head; burning sensation on top and back of  head, arm and back; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6208) via an unspecified route of administration in the right arm on 15Mar2021 at 14:30 (at the age of 52-years-old) as a single dose for Covid-19 immunisation. The patients medical history included hypothyroidism and supraventricular tachycardia. The patient took unspecified medication within two weeks, prior to COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: El9269) via an unspecified route of administration in the left arm on 21Feb2021 at 10:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation and Penicillin on an unknown date for unspecified indication and experienced a Penicillin allergy and codeine on an unknown date for unspecified indication and experienced a drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine .Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the Patient had not tested for COVID-19. On 15Mar2021 at 21:00, patient experienced sharp pain/pressure in chest, elevated heart rate, sharp pains in head accompanied by burning sensation on top and back of head and in arms and back. The patient did not receive any treatment for the reported events. The events resulted in doctor or other healthcare professional office/clinic, and emergency room/department or urgent care visit. The clinical outcome of the chest pain, chest pressure, head pain and burning sensation were not resolved and of the increased heart rate was recovered on unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Full blood count normal, Heart rate increased, Troponin
Clinical narrative: sharp pain/pressure in chest; sharp pain/pressure in chest; elevated heart rate; sharp pains in head; burning sensation on top and back of  head, arm and back; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6208) via an unspecified route of administration in the right arm on 15Mar2021 at 14:30 (at the age of 52-years-old) as a single dose for Covid-19 immunisation. The patients medical history included hypothyroidism and supraventricular tachycardia. The patient took unspecified medication within two weeks, prior to COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: El9269) via an unspecified route of administration in the left arm on 21Feb2021 at 10:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation and Penicillin on an unknown date for unspecified indication and experienced a Penicillin allergy and codeine on an unknown date for unspecified indication and experienced a drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine .Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the Patient had not tested for COVID-19. On 15Mar2021 at 21:00, patient experienced sharp pain/pressure in chest, elevated heart rate, sharp pains in head accompanied by burning sensation on top and back of head and in arms and back. The patient did not receive any treatment for the reported events. The events resulted in doctor or other healthcare professional office/clinic, and emergency room/department or urgent care visit. The clinical outcome of the chest pain, chest pressure, head pain and burning sensation were not resolved and of the increased heart rate was recovered on unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Chest discomfort, Chest pain, Headache, Heart rate increased
Clinical narrative: sharp pain/pressure in chest; sharp pain/pressure in chest; elevated heart rate; sharp pains in head; burning sensation on top and back of  head, arm and back; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6208) via an unspecified route of administration in the right arm on 15Mar2021 at 14:30 (at the age of 52-years-old) as a single dose for Covid-19 immunisation. The patients medical history included hypothyroidism and supraventricular tachycardia. The patient took unspecified medication within two weeks, prior to COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: El9269) via an unspecified route of administration in the left arm on 21Feb2021 at 10:30 (at the age of 52-years-old) as a single dose for COVID-19 immunisation and Penicillin on an unknown date for unspecified indication and experienced a Penicillin allergy and codeine on an unknown date for unspecified indication and experienced a drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine .Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the Patient had not tested for COVID-19. On 15Mar2021 at 21:00, patient experienced sharp pain/pressure in chest, elevated heart rate, sharp pains in head accompanied by burning sensation on top and back of head and in arms and back. The patient did not receive any treatment for the reported events. The events resulted in doctor or other healthcare professional office/clinic, and emergency room/department or urgent care visit. The clinical outcome of the chest pain, chest pressure, head pain and burning sensation were not resolved and of the increased heart rate was recovered on unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Paraesthesia oral
Clinical narrative: numbness and tingling of right side of tongue; numbness and tingling of right side of tongue; This is a spontaneous report from a contactable Pharmacist. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203), via intramuscular route of administration on 27Feb2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. It was unknown if the patient had medical history. It was unknown if the patient had any allergies to food, medications, or other products. It was unknown if the patient was diagnosed with COVID-19 prior to vaccination. It was unknown if the patient had been tested for COVID-19 since the vaccination. It was unknown if the patient received any concomitant medications within two weeks of the vaccination. It was unknown if the patient received any other vaccines within four weeks prior to the COVID vaccine. On 27Feb2021 at 11:00, the patient complained of numbness and tingling of right side of tongue. The physician on duty ordered 25mg per oral (PO) diphenhydramine (BENADRYL) to be given. The patient took diphenhydramine (BENADRYL) and refused water. At 11:10, the patient was checked on by EMS on duty with no changes. At 11:20, no changes to mouth were noted still for patient. At 11:30, there were still no changes and EMS on duty cleared the patient to discharge home after 30 minutes of observation. The patient was informed to seek immediate medical attention if symptoms worsened and the patient communicated understanding. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events numbness and tingling of right side of tongue were unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral, Paraesthesia oral
Clinical narrative: numbness and tingling of right side of tongue; numbness and tingling of right side of tongue; This is a spontaneous report from a contactable Pharmacist. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203), via intramuscular route of administration on 27Feb2021 at 11:00 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. It was unknown if the patient had medical history. It was unknown if the patient had any allergies to food, medications, or other products. It was unknown if the patient was diagnosed with COVID-19 prior to vaccination. It was unknown if the patient had been tested for COVID-19 since the vaccination. It was unknown if the patient received any concomitant medications within two weeks of the vaccination. It was unknown if the patient received any other vaccines within four weeks prior to the COVID vaccine. On 27Feb2021 at 11:00, the patient complained of numbness and tingling of right side of tongue. The physician on duty ordered 25mg per oral (PO) diphenhydramine (BENADRYL) to be given. The patient took diphenhydramine (BENADRYL) and refused water. At 11:10, the patient was checked on by EMS on duty with no changes. At 11:20, no changes to mouth were noted still for patient. At 11:30, there were still no changes and EMS on duty cleared the patient to discharge home after 30 minutes of observation. The patient was informed to seek immediate medical attention if symptoms worsened and the patient communicated understanding. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events numbness and tingling of right side of tongue were unknown at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Acoustic stimulation tests, Food allergy
Clinical narrative: Ringing of ears; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in her left arm on 17Mar2021 at 17:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The medical history included Sjogrens syndrome. The patient was allergic to nuts. Concomitant medications included unspecified multi, cholecalciferol (VIT D3), B complex (MANUFACTURER UNKNOWN), turmeric ((MANUFACTURER UNKNOWN) omega-3 fatty acids (MANUFACTURER UNKNOWN), ascorbic acid (PROBI). Prior to the vaccination; the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 17Mar2021 at 18:00, the patient experienced ringing of ears. The adverse event resulted in a doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of the event ringing of ears was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing of ears; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204), via an unspecified route of administration in her left arm on 17Mar2021 at 17:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The medical history included Sjogrens syndrome. The patient was allergic to nuts. Concomitant medications included unspecified multi, cholecalciferol (VIT D3), B complex (MANUFACTURER UNKNOWN), turmeric ((MANUFACTURER UNKNOWN) omega-3 fatty acids (MANUFACTURER UNKNOWN), ascorbic acid (PROBI). Prior to the vaccination; the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 17Mar2021 at 18:00, the patient experienced ringing of ears. The adverse event resulted in a doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of the event ringing of ears was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling abnormal, Headache, Muscle spasms, Nausea, Pain
Clinical narrative: Bad headache; Severe body aches; severe joint pain; nausea; lite headedness; spasms on  legs, arms and back.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as pre/probiotics (MANUFACTUER UNKNOWN) and women multivitamin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 23:00, the patient had side effects that was as bad as when she had COVID in Dec2020. The patient experienced bad headache, severe body aches, severe joint pain, nausea and some light-headedness. The new symptom that was severe as well was spasms. The patient experienced really bad spasms on her legs, arms and back. They had been hurting so bad that the patient could not even touch them. It was reported that the patient felt like she had all the symptoms of COVID. It had been two days but still the patient felt awful. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The clinical outcome of headache, general body pain, joint pain, nausea, light-headedness and spasms was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: Bad headache; Severe body aches; severe joint pain; nausea; lite headedness; spasms on  legs, arms and back.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as pre/probiotics (MANUFACTUER UNKNOWN) and women multivitamin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 23:00, the patient had side effects that was as bad as when she had COVID in Dec2020. The patient experienced bad headache, severe body aches, severe joint pain, nausea and some light-headedness. The new symptom that was severe as well was spasms. The patient experienced really bad spasms on her legs, arms and back. They had been hurting so bad that the patient could not even touch them. It was reported that the patient felt like she had all the symptoms of COVID. It had been two days but still the patient felt awful. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The clinical outcome of headache, general body pain, joint pain, nausea, light-headedness and spasms was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Dizziness, Headache, Muscle spasms, Nausea
Clinical narrative: Bad headache; Severe body aches; severe joint pain; nausea; lite headedness; spasms on  legs, arms and back.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as pre/probiotics (MANUFACTUER UNKNOWN) and women multivitamin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 23:00, the patient had side effects that was as bad as when she had COVID in Dec2020. The patient experienced bad headache, severe body aches, severe joint pain, nausea and some light-headedness. The new symptom that was severe as well was spasms. The patient experienced really bad spasms on her legs, arms and back. They had been hurting so bad that the patient could not even touch them. It was reported that the patient felt like she had all the symptoms of COVID. It had been two days but still the patient felt awful. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The clinical outcome of headache, general body pain, joint pain, nausea, light-headedness and spasms was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain
Clinical narrative: Bad headache; Severe body aches; severe joint pain; nausea; lite headedness; spasms on  legs, arms and back.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as pre/probiotics (MANUFACTUER UNKNOWN) and women multivitamin (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 23:00, the patient had side effects that was as bad as when she had COVID in Dec2020. The patient experienced bad headache, severe body aches, severe joint pain, nausea and some light-headedness. The new symptom that was severe as well was spasms. The patient experienced really bad spasms on her legs, arms and back. They had been hurting so bad that the patient could not even touch them. It was reported that the patient felt like she had all the symptoms of COVID. It had been two days but still the patient felt awful. The adverse event had not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care. The clinical outcome of headache, general body pain, joint pain, nausea, light-headedness and spasms was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Hyperhidrosis, Pyrexia
Clinical narrative: Lots of appetite; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 03Mar2021 at 12:15 as a single dose for COVID-109 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 12:15, the patient experienced low grade fever on day 2 following the second vaccinations and lots of appetite. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events low grade fever and lots of appetite. The clinical outcomes of the events low grade fever and lots of appetite were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature, Chills, Decreased appetite, Night sweats, Pain
Clinical narrative: Lots of appetite; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 03Mar2021 at 12:15 as a single dose for COVID-109 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 12:15, the patient experienced low grade fever on day 2 following the second vaccinations and lots of appetite. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events low grade fever and lots of appetite. The clinical outcomes of the events low grade fever and lots of appetite were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: Lots of appetite; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 03Mar2021 at 12:15 as a single dose for COVID-109 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 12:15, the patient experienced low grade fever on day 2 following the second vaccinations and lots of appetite. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events low grade fever and lots of appetite. The clinical outcomes of the events low grade fever and lots of appetite were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Increased appetite, Pyrexia
Clinical narrative: Lots of appetite; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 03Mar2021 at 12:15 as a single dose for COVID-109 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 12:15, the patient experienced low grade fever on day 2 following the second vaccinations and lots of appetite. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events low grade fever and lots of appetite. The clinical outcomes of the events low grade fever and lots of appetite were recovering at the time of the report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Pain and swelling under left arm lymph nodes; Pain and swelling under left arm lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208), via an unspecified route of administration in the left arm on 25Mar2021 at 09:30 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included valsartan/ hydrochlorothiazide (HCTZ) (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN), oxybutynin ER (MANUFACTURER UNKNOWN) and meloxicam (MELOXI), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6198), via an unspecified route of administration in the left arm on 04Mar2021 at 12:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 18:00 (reported as second day), the patient experienced pain and swelling under left arm lymph nodes. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events lymph node pain and swollen lymph nodes. The clinical outcomes of the events lymph node pain and swollen lymph nodes were not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus, Urticaria
Clinical narrative: large, itchy hives on right side of myabdomen (looks like a cluster ofmosquito bites) and a few hours laterstarted to get another one in thecenter of my abdomen; large, itchy hives on right side of myabdomen (looks like a cluster ofmosquito bites) and a few hours laterstarted to get another one in thecenter of my abdomen; This is a spontaneous report from a contactable consumer, the patient. A 61-years-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on the right arm on 27Mar2021 at 11:45 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. Medical history included osteoporosis. The patient was allergic to penicillin, amoxycillin, various foods and seasonal allergies. Concomitant medications included fluticasone propionate (FLONASE), teriparatide (FORTEO) received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 07:00, the patient experienced cluster of large, itchy hives on right side of abdomen (which looks like a cluster of mosquito bites) in the morning and a few hours later started to get another one in the centre of abdomen. No therapeutic measures were taken for the adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of itchy hives on right side and centre of abdomen was unknown.   No follow-up attempts are need; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Headache, Injection site pain, Injection site warmth, Malaise
Clinical narrative: Headache.; Muscle aches especiallyaround the injection site; Injection site feels warm or hot.; Body temperature changes from hot to freezing in seconds.; Tired; feeling unwell; feverish but no fever; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 02:15 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had history of allergy to codeine. Concomitant medications included paracetamol (TYLENOL), naproxen (MOTRIN), mepyramine maleate, mepyramine maleate, paracetamol (PAMPRIN), mefenamic acid (ADVIL) and melatonin (MANUFACTURER UNKNOWN) all for unknown indication on unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021, at 12:00 the patient experienced headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell. No therapeutic measures were taken for the events. The adverse events did not result in doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature abnormal, Fatigue, Headache, Injection site pain, Malaise
Clinical narrative: Headache.; Muscle aches especiallyaround the injection site; Injection site feels warm or hot.; Body temperature changes from hot to freezing in seconds.; Tired; feeling unwell; feverish but no fever; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 02:15 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had history of allergy to codeine. Concomitant medications included paracetamol (TYLENOL), naproxen (MOTRIN), mepyramine maleate, mepyramine maleate, paracetamol (PAMPRIN), mefenamic acid (ADVIL) and melatonin (MANUFACTURER UNKNOWN) all for unknown indication on unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021, at 12:00 the patient experienced headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell. No therapeutic measures were taken for the events. The adverse events did not result in doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Vaccination site warmth
Clinical narrative: Headache.; Muscle aches especiallyaround the injection site; Injection site feels warm or hot.; Body temperature changes from hot to freezing in seconds.; Tired; feeling unwell; feverish but no fever; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27Mar2021 at 02:15 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had history of allergy to codeine. Concomitant medications included paracetamol (TYLENOL), naproxen (MOTRIN), mepyramine maleate, mepyramine maleate, paracetamol (PAMPRIN), mefenamic acid (ADVIL) and melatonin (MANUFACTURER UNKNOWN) all for unknown indication on unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021, at 12:00 the patient experienced headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell. No therapeutic measures were taken for the events. The adverse events did not result in doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, muscle aches especially around the injection site, warm or hot at Injection site, feverish but not fever, body temperature changes from hot to freezing in seconds, tired and overall feeling unwell were not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oral lichenoid reaction
Clinical narrative: Oral lichenoid reaction, very painful.; This is a spontaneous report from a contactable other-health care professional, the patient. A 48-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: EN6204), via an unspecified route of administration in the left arm on 24Mar2021 at 15:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included pencillin allergy. Concomitant medications included paroxetine hydrochloride (PAXIL) 10 mg and gabapentin (NEURONTIN) 600 mg received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19. On 26Mar2021, the patient experienced oral lichenoid reaction, very painful and the doctor visit was pending. It was unknown if the patient received treatment for the event. On 27Mar2021, the patient underwent a PCR test (Nasal swab) and the result was negative. The clinical outcome of oral lichenoid reaction was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oral lichenoid reaction, SARS-CoV-2 test
Clinical narrative: Oral lichenoid reaction, very painful.; This is a spontaneous report from a contactable other-health care professional, the patient. A 48-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: EN6204), via an unspecified route of administration in the left arm on 24Mar2021 at 15:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included pencillin allergy. Concomitant medications included paroxetine hydrochloride (PAXIL) 10 mg and gabapentin (NEURONTIN) 600 mg received within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19. On 26Mar2021, the patient experienced oral lichenoid reaction, very painful and the doctor visit was pending. It was unknown if the patient received treatment for the event. On 27Mar2021, the patient underwent a PCR test (Nasal swab) and the result was negative. The clinical outcome of oral lichenoid reaction was unknown.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8734) via unspecified route of administration in the left arm on 28Mar2021 at 13:45 (at the age 0f 54-year-old), as a single dose for COVID-19 immunisation. Medical history included sleep apnea from an unknown date. Patient had no known allergies to medications, food or other products. Concomitant medications included oxymetazoline hydrochloride (AFRIN) as necessary for allergies taken within two weeks of vaccination. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since vaccination, the patient had not tested for COVID-19.  On 28Mar2021 at 17:00 patient experienced tinnitus. The patient had not received any treatment for the clinical event. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event tinnitus was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.